Orkla ASA (ORK) Earnings Call Transcript & Summary
May 20, 2026
What were the key takeaways from Orkla ASA's May 20, 2026 earnings call?
In Orkla ASA's Q1 2026 earnings call, the company reported operating revenues of NOK 17.4 billion, a 1.3% increase year-over-year, while adjusted earnings per share rose 4% to NOK 1.75. The organic growth of 4.9% was driven by strong performance across portfolio companies, particularly in Orkla Food Ingredients and Orkla Snacks. Management maintained guidance for the year, indicating that while input costs are expected to rise, they do not foresee a repeat of the inflationary pressures experienced post-pandemic.
What topics did Orkla ASA cover?
- Organic Growth Performance: Orkla achieved organic growth of 4.9% in Q1 2026, with contributions from all portfolio companies. CEO Nils Selte noted, 'Growth was particularly high in Orkla Food Ingredients, Orkla Snacks and Orkla Food.'
- Challenges in Orkla Health: Orkla Health is facing a challenging year, with management indicating, 'We don't expect that to be satisfactory for this year in total.' The closure of three factories is expected to impact profitability negatively in the short term.
- Jotun's Performance and Outlook: Jotun reported a 16% underlying EBIT growth, although profit to Orkla declined by 5.8%. Management highlighted, 'Jotun faces a high degree of uncertainty related to the Middle East conflict,' which may impact future performance.
- Input Cost Pressures: Management acknowledged upward pressure on energy, freight, and packaging-related costs. They stated, 'We do not expect an inflationary impact comparable to the post-pandemic period,' suggesting a more controlled approach to cost management.
- Strategic Portfolio Adjustments: Orkla is reducing complexity within its portfolio, including targeted divestments. Selte mentioned, 'We benefit from our strong balance sheet and a diversified portfolio,' indicating readiness for value-accretive opportunities.
What were Orkla ASA's May 20, 2026 results?
- Revenue: NOK 17.4 billion (vs NOK 17.2 billion est, +1.3% YoY)
- Adjusted EPS: NOK 1.75 (vs NOK 1.68 est, +4% YoY)
- Organic Growth: 4.9% (vs 4.5% est)
- Underlying EBIT Growth: 3% (vs 4% est)
- EBIT Margin: 10.5% (rolling 12-month basis)
- Net Debt: NOK 13.6 billion (1x EBITDA)
Orkla ASA's Q1 results reflect solid organic growth and a commitment to shareholder returns, despite challenges in specific segments like Orkla Health. The management's cautious outlook on input costs and geopolitical risks suggests a need for close monitoring. Investors should watch for developments in cost management and the performance of Jotun, which is critical to Orkla's overall profitability.
Earnings Call Speaker Segments
Annie Bersagel
executiveGood morning, everyone, and welcome to the presentation of Orkla's first quarter results. I'm Annie Bersagel, Head of Investor Relations and Communications. To start, our President and CEO, Nils Selte, will give a presentation summarizing the latest developments for the quarter. Following that, EVP and CFO Arve Regland will go through more detail on the financials as well as on the individual portfolio companies. Then Nils will wrap up with a few closing remarks before we move over to our Q&A. Just as a reminder on the procedures for Q&A, there's a web Q&A form you can send questions through at any time, but first we'll do a video Q&A with our analyst community, and after that we'll move over to questions from the web. With that, I'd like to turn it over to you, Nils.
Nils K. Selte
executiveThank you, Annie, and good morning to all of you. I want to open today's presentation with something personal. On May 4th, Orkla's Chairman, Stein Erik Hagen, passed away suddenly. For more than 25 years as an active owner, Stein Erik made his mark on Orkla. He carried an entrepreneurial drive into the boardroom and played a key part in helping Orkla take calculated risk with an investor mindset. He also gave strong backing to Orkla's recent transformation into an industrial investment company. He will be deeply missed. In that spirit, I'll now move on to our review of the quarter, keeping in mind the values and ambition that Stein Erik instilled in the company. Organic growth came in at 4.9% for the quarter, with every portfolio company contributing. Growth was especially strong in Orkla Food Ingredients, Orkla Snacks, and Orkla Foods. Underlying EBIT (adj.) grew 3%, as volume/mix growth was partly offset by higher costs. Earnings per share (adj.) rose 4% to 1.75 kroner. Alongside the quarterly result, there has also been a change in the Board of Orkla Foods. Gilles Meurelle? will take over as the new Board Chair from June 1st. He brings over 30 years of executive experience from international branded consumer goods companies, including Mars.
Nils K. Selte
executiveI'd like to express appreciation to Xavier Belison, the former Board Chair, for what he has contributed to Orkla Foods across the past three years. In the first quarter, volume/mix growth came in at 3.2% — yet another quarter showing volume growth. On an underlying basis, performance was better, helped by ongoing gains in commercial capabilities, plus a modest lift from Easter effects. Turning to EBIT development throughout the portfolio: Jotun's operational performance is still strong, posting 16% underlying EBIT growth for the quarter. Across the consolidated portfolio, Orkla ASA included, underlying EBIT (adj.) growth stood at 3%. Orkla Snacks and Orkla Food Ingredients were particularly positive contributors this quarter, whereas the negative trend at Orkla Health weighed on the consolidated results. Operational performance at Orkla India was also stronger than the underlying EBIT (adj.) growth figure suggests, because of incentives obtained from the Government of India in the prior year. Let me offer a short comment regarding the war in the Middle East. First quarter results were not materially impacted by the conflict. Direct effects stayed limited, most notably at Jotun and Orkla India, while the wider portfolio was largely untouched. Going forward, indirect effects look more uncertain. Within the consolidated portfolio, we observe upward pressure on input costs tied to energy, freight, and packaging.
Nils K. Selte
executiveThe situation differs from one part of the portfolio to another, and the mitigating actions are adapted to match. Jotun will be covered specifically by Arve. Right now, we don't anticipate an inflationary effect on the scale of what followed the pandemic, though we are watching how things develop very closely. In brief, the EBIT (adj.) margin came in at 10.5% measured on a rolling 12-month basis. I'll finish with an update on the three years financial targets for the consolidated portfolio that were set at the 2023 Capital Markets Day. Underlying EBIT (adj.) got off to a slower start in the first quarter, yet it stays on track against our compounded growth target for the strategy period. Our EBIT (adj.) margin stayed inside the target range, and return on capital employed held steady at 12.4%. I'll now pass things to Arve, who will give you more detail on the financials.
Arve Regland
executiveThank you, Nils, and good morning. Before I move on to the specific portfolio company, I'll give a quick overview of the group's financial performance in the quarter. Starting with the income statement: reported operating revenues rose 1.3% to 17.4 billion, while EBIT (adj.) fell 1.3%. The gap between the reported and underlying figures that Nils referred to stems mainly from negative currency effects and a smaller contribution from Orkla Real Estate. Other income and expenses came in at -45 million, largely tied to M&A costs and restructuring projects currently underway in Orkla Foods and Orkla Health. Profit from Jotun was down 5.8% in the quarter, and I'll return to Jotun in more detail shortly. We also note that net interest cost fell thanks to lower interest rates and reduced debt levels, which contributed to the 4% rise in adjusted earnings per share. Cash flow from operations reached 1.1 billion, declining year-on-year because of higher working capital from strong sales late in the quarter and increased net replacement investments. We received the first installment of the 2025 Jotun dividend, which arrived in the second quarter last year. Cash flow before capital allocation came to 1 billion, matching last year.
Arve Regland
executiveNow moving to the capital allocation bridge: during the quarter we bought back stock worth 1 billion 1 billion, under the repurchase program we announced in November. Roughly 100 million of expansion investments went toward boosting production capacity throughout the portfolio. Company purchases comprise a bolt-on acquisition within Orkla Food Ingredients. Orkla closed the quarter with net debt of 13.6 billion, which equals 1 times EBITDA, and 0.8 times when Orkla Food Ingredients is excluded. Moving on to the portfolio companies. As Nils said, Jotun delivered yet another strong quarter. Although currency effects once again shaped the reported figures, underlying revenue growth came in at 9.4%, with gains in every segment and region. Positive contributions came from higher volumes and favorable mix effects, among them stronger premium sales. Reported operating profit stood at 5.3%, and 16% once negative currency effects are adjusted for. This reflected both higher sales and an improved gross margin. Profit from Jotun to Orkla fell by 5.8% to 617 million. That drop stems from financial items, owing to smaller currency hedging gains and currency losses on intercompany loans. Jotun confronts considerable uncertainty tied to the Middle East conflict. Above all, every employee in the region is safe. Jotun saw lower revenues from business units in the region during March.
Arve Regland
executiveMeanwhile, the units impacted accounted for just 8% of Jotun Group revenues in the quarter. The indirect consequences affect the paints and coating industry on a global basis. How far this ultimately extends hinges on the way the conflict evolves, yet a negative impact will occur in any case. Part of Jotun's sourcing base is tied to movements in global oil prices, and exposure is greatest in the Marine and Protective segments. Jotun projected considerable increases in input costs starting in the second quarter, which are anticipated to squeeze gross margins. Steps are being taken to mitigate the effect via price increases, alternative sourcing initiatives, continued cost control, and postponed Middle East investments. Even so, the mitigating actions will need time to materialize, and demand-related effects remain uncertain. Jotun possesses substantial experience in managing geopolitical instability, and gains advantage from a globally diversified portfolio along with a clear and consistent long-term strategy. Turning to Orkla Foods, organic growth for the quarter was 3.5%, with 2.3% coming from volume/mix. Organic growth was stronger in the prioritized growth platforms than in the remainder of the portfolio. Volumes received some support from positive Easter phasing effects in Sweden and Norway, as well as from the comparison with a quarter that had weaker volumes, particularly in Norway last year.
Arve Regland
executiveOrkla Foods kept rolling out the commercial tools that were presented at last year's Capital Markets Update. Volume growth was the primary driver behind the 5.1% rise in underlying EBIT. Within Orkla Snacks, volume/mix growth got a contribution from all three categories, with the confectionery category leading on the strength of a cocoa-related recovery, alongside strong Bubs demand and favorable Easter phasing effects. The EBIT gain came from higher volumes and from better contribution out of cocoa. The Bubs US rollout carried on through the first quarter. It is now in over 40,000 stores throughout the US, and Bubs also recently introduced a global limited edition collaboration with H&M Beauty. Orkla Snacks is also continuing to put investment into brand building in the US market, so Bubs US was not a meaningful EBIT contributor during the quarter. Organic growth at Orkla Home & Personal Care reached 3.3%, and underlying EBIT rose 9.1%. Volume growth in Norway and Sweden mirrored both continued favorable underlying development and the timing of Easter. The increase in underlying EBIT was fueled by volume growth and cost control. Market share development was positive in Norway and Finland alike, whereas Sweden's development held stable. Orkla Food Ingredients posted organic growth of 5.4%, powered by volume growth in every cluster.
Arve Regland
executiveEaster’s timing also gave the Bakery cluster a lift. We saw 10% growth in underlying EBIT, with Sweet Ingredients leading the way as volume, mix, price, and efficiency gains each made a positive contribution. Bakery likewise contributed to EBIT growth, whereas Plant Based saw a slight decline caused by product mix effects. In Orkla Health, organic growth of 1.3% came mainly from price across most markets. Apart from the isolated phasing effects from Q4 to Q1 that we communicated earlier, volume development was weak in the food supplements and functional personal care categories. Cod liver oil prices continued to weigh on both volume and margins. Lower volumes, negative mix effects, and higher costs pushed underlying EBIT down. Orkla Health is implementing steps to lower its cost base and has announced the planned closure of three factories, two of which relate to the food supplements business. Although these actions will enhance profitability over the long term, we expect negative impacts from winding down the factories as we move forward. Against this background, we anticipate that this year will be challenging for Orkla Health. Management is presently shaping the long-term strategy under the new operating model and will present it at the Capital Markets Day in December. Orkla India posted organic growth of 2.8% for the quarter, primarily driven by price increases aimed at offsetting higher costs for key raw materials.
Arve Regland
executiveIf we factor in the NOK 26 million in grants that came from the Government of India during the first quarter of last year, organic growth stood at 6.5%. Underlying EBIT fell 7.8%, with part of that stemming from increased freight costs tied to the Middle East conflict. Once government grants are excluded, underlying growth came to 16%. At the European Pizza Company, every business posted same-store sales growth, and overall organic growth reached 4.9% while consumer sales rose 8.9%. Consumer sales growth was driven by Kotipizza in Finland, which saw 14% growth thanks to a refreshed brand strategy and focused growth initiatives. Underlying EBIT was up 13%, with support from Kotipizza and New York Pizza. It's encouraging to see the two smallest portfolio companies keep up their positive momentum. Orkla Health Care posted 4.4% growth for the quarter, along with 10% growth in underlying EBIT. Health and Sports Nutrition Group achieved organic growth of 3.4% and underlying EBIT growth of 26%. With that, Nils, I'll turn it back to you for the closing remarks.
Nils K. Selte
executiveThanks, Arve. Turning back to the three strategic priorities we've set: we keep generating organic value inside the current portfolio, and the progress there matches our consolidated targets. We're also cutting complexity throughout the portfolio, which includes targeted divestments at the level of the portfolio companies. Among the recent examples are the sales by Orkla Food Ingredients and Orkla Snacks of a non-core operation in Iceland. And finally, in times such as these, our strong balance sheet and diversified portfolio work to our advantage. That gives us the flexibility to pursue value accretive opportunities if they come up. With that, Arve and I are glad to take your questions. Thank you.
Annie Bersagel
executiveThanks for joining us again — we're set to kick off the Q&A now. First up is the video Q&A session with the analysts, and you're also welcome to send in questions through the web, which we'll pick up after that. Our first question appears to be from Ole-Martin Westgaard at DNB Carnegie. Please don't forget to unmute yourself as well. Hang on a second, we're having a bit of an issue with the audio.
Ole Martin Westgaard
analystMoving on to the next question.
Annie Bersagel
executiveYeah, we can hear you now.
Ole Martin Westgaard
analystGreat, thanks. So you mentioned that Easter had some effect during the quarter. Could you give us a little more detail on how we ought to think about that, and what the possible effects of these timing shifts might be on the second quarter?
Arve Regland
executiveRight, we haven’t put a number on it, but I’d say it isn’t a major factor behind the growth — more of a supportive effect for Q1. And usually, if it supports Q1, then Q2 tends to see the reverse effect.
Ole Martin Westgaard
analystBut
Nils K. Selte
executiveWe've been saying that Q1 still fairly reflects the underlying trend, and that's what we also want to highlight.
Ole Martin Westgaard
analystAll right. So, regarding Health: you point out that this year will be a tough one for that segment and that you're shutting three plants. Could you share more detail on what the potential cost might be, how large those factories are, and when that expense will show up on the P&L? And on that remark about this being a challenging year — does that relate more to the demand side, or does it reflect the cost side tied to closing those plants?
Arve Regland
executiveBeginning with that final point: when I describe the year as challenging, I'd say that reflects the fact that, looking back at the Orkla Health ambitions laid out at the Capital Markets Day in 2023, they are clearly trailing the plans. What we see is that they continue to struggle both with volume growth across several categories and with a cost base that is too high, plus an increase in raw materials in certain of those categories. Taken together, that is guidance that overall profitability in Orkla Health, we don't expect it to be satisfactory for this year in total. When we are 30% back on Q1, I wouldn't call that representative for the full year, but it still serves as guidance that challenging times lie ahead for the coming quarters, both on top line and on the cost base as well. Then we have these factory closures, which will add to that. We say that these three factories will be closed up until the end of next year, and it will be a gradual impact over the coming quarters. Internally, we don't know yet either how that will affect the cost space, but obviously it will mean a double cost during a wind-down period in the coming quarters that will have a negative impact on the quarters in the short end, though with clear ambitions to increase profitability in the longer term.
Ole Martin Westgaard
analystAll right, so lastly on Bubs and the US launch — it seems pretty meaningful. Could you give us a sense of how much it added to organic growth overall in Snacks? I get that the effect on EBIT was likely not all that big, but what about the impact on organic growth?
Arve Regland
executiveThat's certainly part of the really encouraging momentum in Snacks, though I'd say the rebound in cocoa within the chocolate segment plays the larger role — even so, the exceptionally strong demand for Bubs also adds to the volume gains we saw in the confectionery category within Snacks during this quarter.
Ole Martin Westgaard
analystAll right, thanks.
Annie Bersagel
executiveThere's a question coming from Andrei Condrea at UBS.
Andrei Condrea
analystGood morning, and many thanks for taking my questions. I have two, please. Turning to the outlook for the rest of 2026: much has shifted since your last full-year earnings report. How has your thinking evolved in light of that, given what we're clearly observing on the ground plus the effect on costs and possibly demand over the longer term? Related to that, several of your peers have published various oil price scenarios and potential impacts from the dollar and the NOK. Is there anything you can share on that front, and what mitigation options do you have available? Just on Jotun: clearly it accounts for a big share of your profits owing to its outstanding growth, but how are they thinking, or how are you thinking, about the 2026 outlook, especially regarding top line and profits and the contribution to your business? Thank you.
Nils K. Selte
executiveTypically, we don’t provide guidance on that—or at least we don’t give guidance, to be clear. I think Jotun has been—and we’ve said this in the report as well—that there will be a significant rise in input costs during this year. We aren’t giving a specific figure for that increase. As for our consolidated portfolio companies, our guidance is that this will affect energy prices, freight prices, and packaging in particular. You’ll also see some inflationary impact in other parts of the portfolio too. As we noted in the report, this is something that is managed through our portfolio companies and discussed in the various boardrooms. This time, we don’t anticipate the same enormous effect we saw from post-pandemic inflation. What we’ll see now is much more targeted types of initiatives to mitigate this through the portfolio companies.
Andrei Condrea
analystGot it. Thanks.
Annie Bersagel
executiveI believe the next question comes from Petter Nystrøm at ABG Sundal Collier.
Petter Nystrøm
analystThanks for taking my question. I believe I have three. To follow up on the Health question that Ole-Martin raised: can you say whether the cost — or should we call it the restructuring cost here — will be booked under the segment or under other income and expenses?
Nils K. Selte
executivePetter, it's too soon for us to offer any clear guidance on that. Orkla Health's board has made the decision to shut down these three factories. The wind-down will be gradual over the coming quarters, running until the end of next year. As for any cost figures—double costs, higher costs, and potentially write-downs of balance sheet items and so on—nothing has been quantified internally either. I'm unable to answer that right now.
Petter Nystrøm
analystGot it. Turning to India, how should we view those government grants for the rest of 2026? In the past, we've seen this segment receive such grants from time to time. How should we think about that for the remainder of the year?
Nils K. Selte
executiveWe can't offer any guidance on whether we'll get any grants for the rest of the year. That depends on production. It's really difficult to project ahead whether we'll be able to receive anything. What we can tell you is that the existing program concludes at the end of March 2027. Whether we'll receive anything, and how that would affect the numbers, we're unfortunately not in a position to guide on. All right,
Petter Nystrøm
analystAppreciate it. So one last thing, and this is for the branded consumer goods portfolio companies: Nils, Arve, I believe the two of you pointed out that you're encountering increased costs for freight, packaging, and energy. Will that effect begin showing up as early as the second quarter, or does it land more in the second half?
Nils K. Selte
executiveFirst off, Petter, that situation shifts practically daily, so giving you guidance on it is really difficult. We aren't anticipating enormous impacts in Q2 — what we will tell you is that it should build up steadily across the year, and that's the only guidance we're providing.
Petter Nystrøm
analystThat's great, thanks. I'll get back into the queue.
Annie Bersagel
executiveI believe our next question comes from Håkon Fuglu at SEB.
Håkon Fuglu
analystYes, good morning, everyone. Thanks for taking my question. It concerns Jotun: you mentioned price increases that were already in place during the first quarter. Can you put a number on that?
Nils K. Selte
executiveAre you asking about the pricing of raw materials, Håkon?
Håkon Fuglu
analystActually, no — that pricing pressure gets passed along to customers.
Nils K. Selte
executiveRegarding the temporary shutdown of factories in the Middle East for a brief stretch due to the Middle East crisis, that of course had a slight impact on the Q1 figures, though there were no major effects whatsoever. When you look at Jotun, 8% of their business is directly impacted by the Middle East crisis.
Håkon Fuglu
analystRight, but didn't you mention that you'd already increased prices to your end customers as a way to offset the input costs?
Nils K. Selte
executiveI don't believe we're going to give guidance on that. What I'd say is that, since we run these portfolio companies on a consolidated basis, we allow them the freedom to act. Jotun operates its business in that same manner. Across the various regions and countries around the world, Jotun takes different measures.
Håkon Fuglu
analystThanks. I just want to follow up on Jotun: how would you compare this kind of raw material price crisis with what we saw in 2022?
Nils K. Selte
executiveNo, overall I wouldn’t anticipate the same enormous impact that we saw for both the consolidated portfolio companies and Jotun. As I mentioned, this isn’t comparable to what we witnessed back during the post-pandemic inflation period.
Håkon Fuglu
analystAppreciate it. I'll get back in line.
Annie Bersagel
executiveLooks like that was the final question on video, and I don't see any coming in from the web. So before we wrap up, I'd like to remind everyone that our Q2 results come out on August 20th. Beyond that, thanks for being with us, and enjoy the rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Orkla ASA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Orkla ASA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Orkla ASA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.